Amneal's itraconazole ANDA gets labeling supplement approved by FDA
FDA approved a labeling supplement for Amneal's generic itraconazole capsules; the record's listed status date falls in the future, an apparent data entry issue.
This week's filing tracker shows one regulatory update for Amneal Pharmaceuticals.
- Amneal received FDA approval for a labeling change to its generic itraconazole 100mg oral capsules under ANDA205080, submission number 20, a labeling submission type1. The record lists a submission status date of 2026-09-14, which is a future date and likely reflects a data entry or database formatting issue rather than an actual approval date; the underlying approval status itself is confirmed as "AP" in the source.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.